Last reviewed · How we verify
PART 1: Double-blind Placebo-controlled
PART 1: Double-blind Placebo-controlled is a SSRI Small molecule drug developed by Sun Pharmaceutical Industries Limited. It is currently in Phase 3 development for Major depressive disorder, Generalized anxiety disorder.
This drug is a selective serotonin reuptake inhibitor.
This drug is a selective serotonin reuptake inhibitor. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | PART 1: Double-blind Placebo-controlled |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Drug class | SSRI |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce symptoms of depression.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
Key clinical trials
- A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease (PHASE1)
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (PHASE3)
- Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1 (PHASE1, PHASE2)
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
- Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (PHASE3)
- A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants (PHASE1)
- Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects (PHASE1)
- A PhaseⅠ Study of HW252001 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PART 1: Double-blind Placebo-controlled CI brief — competitive landscape report
- PART 1: Double-blind Placebo-controlled updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI
Frequently asked questions about PART 1: Double-blind Placebo-controlled
What is PART 1: Double-blind Placebo-controlled?
PART 1: Double-blind Placebo-controlled is a SSRI drug developed by Sun Pharmaceutical Industries Limited, indicated for Major depressive disorder, Generalized anxiety disorder.
How does PART 1: Double-blind Placebo-controlled work?
This drug is a selective serotonin reuptake inhibitor.
What is PART 1: Double-blind Placebo-controlled used for?
PART 1: Double-blind Placebo-controlled is indicated for Major depressive disorder, Generalized anxiety disorder.
Who makes PART 1: Double-blind Placebo-controlled?
PART 1: Double-blind Placebo-controlled is developed by Sun Pharmaceutical Industries Limited (see full Sun Pharmaceutical Industries Limited pipeline at /company/sun-pharmaceutical-industries-limited).
What drug class is PART 1: Double-blind Placebo-controlled in?
PART 1: Double-blind Placebo-controlled belongs to the SSRI class. See all SSRI drugs at /class/ssri.
What development phase is PART 1: Double-blind Placebo-controlled in?
PART 1: Double-blind Placebo-controlled is in Phase 3.
What are the side effects of PART 1: Double-blind Placebo-controlled?
Common side effects of PART 1: Double-blind Placebo-controlled include Nausea, Headache, Dizziness, Insomnia.
What does PART 1: Double-blind Placebo-controlled target?
PART 1: Double-blind Placebo-controlled targets Serotonin transporter and is a SSRI.
Related
- Drug class: All SSRI drugs
- Target: All drugs targeting Serotonin transporter
- Manufacturer: Sun Pharmaceutical Industries Limited — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Compare: PART 1: Double-blind Placebo-controlled vs similar drugs
- Pricing: PART 1: Double-blind Placebo-controlled cost, discount & access